Abstract
Background/Objectives: Conventional anticancer drugs often exhibit limited solubility and bioavailability due to unfavorable physicochemical properties and inherent physiological barriers. To overcome these persistent challenges, nanocarriers have been developed to enhance drug bioavailability and therapeutic efficacy. Among these, lipid and polymeric nanocarriers (LP-NCs) have emerged as particularly promising candidates for anticancer drug delivery. These systems can be engineered for targeted delivery and tailored to respond to specific stimuli, thereby enhancing their therapeutic potential. A notable advancement in this field is the development of smart light-responsive LP-NCs, which demonstrate superior performance over conventional nanocarriers by enabling controlled drug release in response to external light stimuli. Methods: This study presents a meta-analysis based on a curated selection of publications from multiple scientific databases and literature sources. The objective was to evaluate whether light-responsive LP-NCs offer superior anticancer drug bioavailability and therapeutic efficacy compared with their conventional counterparts. The primary outcome measure was the pharmacokinetic parameter area under the curve (AUC), derived from in vivo animal studies. Results: The analysis revealed a significant increase in AUC for light-responsive LP-NCs, indicating improved drug bioavailability and prolonged systemic exposure. Conclusions: These findings highlight the potential of LP-NCs as a promising strategy for enhancing targeted anticancer drug delivery. This approach could pave the way for more effective therapeutic interventions and warrants further investigation in future research and clinical trials.